News

A FMCG company announced an interim dividend of Rs 160 per equity share for the financial year 2025-26. The dividend includes a one-time special payout of Rs 50 per share despite a 14.7 per cent year-on-year decline in net profit to Rs 77.6 crore from Rs 91 crore in the same period last year.

The company said the dividend will be paid on or before March 4, 2026. The record date for eligibility for the interim dividend has been fixed as February 12, 2026.

The company's previous dividend payouts include a final dividend of Rs 45 per share declared on August 22, 2025, with a record date of August 22, 2025.

The company had declared an interim dividend of Rs 80 per share on February 21, 2025, with a record date of February 21, 2025, and a final dividend of Rs 60 per share in November 2024, with book closure from November 29 to December 5, 2024.

The company under discussion is Procter & Gamble Health (PGHL).

PGHL operates in the pharmaceutical segment and is listed on the BSE 1000 index. It is part of the Procter & Gamble group, which has a global presence in approximately 70 countries with brands including Ambi Pur, Ariel, Gillette, Braun, Head & Shoulders, Olay, Oral-B, Pampers, Pantene, Herbal Essences, Tide, Vicks, and Old Spice.

PGHL is one of India’s largest vitamins, minerals, and supplements (VMS) companies. It manufactures and markets products including Neurobion, Livogen, SevenSeas, Evion, Polybion, and Nasivion. The company said it focuses on products for a healthy lifestyle and improved quality of life.

PGHL shares were closed at Rs 5,404, up Rs 210.25 or 4 per cent on Monday. The stock opened at Rs 5,274, touched a high of Rs 5,415.95 and a low of Rs 5,240 during the session. The stock’s 52-week high is Rs 6,700, and its 52-week low is Rs 4,916. The company has a market capitalisation of Rs 8,922.17 crore.

The stock has shown mixed movements over different periods. It gained 3.02 per cent in one week, but fell 3.48 per cent in one month and 7.83 per cent in three months.

Over six months, it declined 15.09 per cent, while the one-year fall was 1.28 per cent. Over three years, the stock rose 15.01 per cent, and over five years fell 26.48 per cent. Over ten years, the stock gained 676.89 per cent.

The company’s EBITDA declined 10.5 per cent to Rs 110.6 crore from Rs 123.6 crore, while operating margins contracted to 29.6 per cent from 39.9 per cent in the year-ago quarter.

Revenue for the quarter grew 20.7 per cent year-on-year to Rs 374 crore from Rs 309.8 crore. The company said sales growth reflected strong top-line momentum despite a moderation in profitability.

Procter & Gamble Health reported sales of Rs 368 crore for the December quarter, up 21 per cent from a year ago. Profit after tax for the quarter stood at Rs 78 crore.